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A Slippery Cause of a Slimy Problem: Mucin Induction by an
Esterified Lipid
Secreted gel-forming mucins (1) are key components of mucociliary
transport, a vital airway innate defense mechanism (2). Mucin and
mucus alterations are present in asthma (3), cystic fibrosis (4), and
chronic bronchitis (5), and mucin gene polymorphisms are also
implicated in the pathogenesis of idiopathic pulmonary fibrosis (6).
Increased numbers of mucin-producing goblet cells at locations
where they are normally present (hyperplasia) or absent
(metaplasia) are pathognomonic responses of the airways to diverse
environmental stimuli. Although they are clearly important and
protective at homeostatic levels, mucin and mucus are likely
harmful when produced in excess, as most vividly and tragically
illustrated in fatal asthma (Figure 1). Importantly, specific therapies
targeting mucin hypersecretion in asthma and other lung
pathologies are not currently available.
Many signaling pathways increase mucin gene expression
and glycoprotein secretion. Most relevant to the lung and asthma,
the mucin MUC5AC is induced by the T-helper cell type 2 (Th2)
mediator IL-13 in human airway epithelial cells (7). In this issue
of the Journal, Zhao and colleagues (pp. 692–701) (8) extend
previous studies showing that elevated 15-lipoxygenase-1 (15LO1)
expression, activity, and responsiveness to IL-13 occur in airway
epithelial cells from asthmatics versus healthy controls, that 15LO1
expression correlates with asthma severity, and that IL-13–induced
15LO1 expression stimulates production of the lipid mediator
15-hydroxyeicosatetraenoic acid (15-HETE) esterified to
phosphatidylethanolamine (15-HETE-PE) (9, 10).
In the current study, Zhao and colleagues used long-term,
established airway epithelial cell cultures from both asthmatics and
healthy donors to address whether 15-HETE-PE directly induces
mucin gene expression and glycoprotein production, and to
elucidate the relevant signaling mechanisms involved. Interestingly,
differences in 15LO1 expression and response to IL-13 between
asthmatic and nonasthmatic subjects did not persist after extended
culture. In this study, the basal media was supplemented with
equimolar amounts of linoleic acid and arachidonic acid to ensure
that substrate availability was not rate limiting. In the presence of the
linoleic acid/arachidonic acid supplement, 15LO1 preferentially
generated 15-HETE-PE and not 13-hydroxyoctadecadienoic
acid (13-HODE) or esterified 13-HODE-PE, supporting the
importance of the specific conjugated metabolite. An extended
half-life of the 15-HETE-PE–generating 15LO1 protein, even after
IL-13 removal, was reported, suggesting the possibility of
sustained effects. Elegant 15LO1 small interfering RNA studies in
primary airway epithelial cell air–liquid interface cultures and the
use of a selective 15LO1 inhibitor (BLX2477) showed decreased
IL-13–induced FOXA3 expression, enhanced FOXA2 expression,
and reduced expression of MUC5AC and periostin. Direct
addition of 15-HETE-PE to the cells, without added IL-13,
recapitulated many of the key effects on airway epithelial cells,
suggesting the importance of this specific lipid mediator in
Th2-type mucin hyperproduction.
Like all good work, the current study raises several important
questions and suggests future directions for research in the field. Does
the 15LO1/15-HETE-PE pathway induce FOXA3 and MUC5AC
in vivo in animals or humans, and is 15-HETE-PE elevated in the
asthmatic airway? Can it serve as a biomarker of severe asthma?
Is 15-HETE-PE a key mediator of mucin hyperproduction by
non–Th2-type stimuli, and does it play a role in other mucin
hypersecretory pathologies? Are there functional polymorphisms in
the gene encoding 15LO1, and are these variants associated with
altered MUC5AC expression/mucus hypersecretion and/or increased
asthma risk? What is the effect of exogenous 15-HETE-PE on airway
epithelial cell morphology? Does it increase MUC5AC mRNA and
protein from the same number of goblet cells, or does it increase
goblet cell numbers? Finally, can specific 15LO1 inhibitors (11) or
15-HETE-PE–selective antagonists be developed, and will they be
effective therapies for asthma and other lung diseases characterized
by excessive mucus secretion?
Figure 1. Mucin hypersecretion in a case of fatal asthma. (A) The gross lung specimen will not deflate. The inset illustrates obstruction of bronchial lumens
with copious mucoid secretions. (B) Alcian blue/periodic acid Schiff staining shows nearly complete blockage of an extremely constricted small airway.
Scale bar: 200 mm.
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It is becoming clear that too much slime (mucin/mucus) in the
airway (mucin hypersecretion) is a defining feature of many lung
diseases, including asthma. Slippery (lipid) mediators are especially
important, as illustrated by their role in aspirin-exacerbated airway
disease (12, 13) and the success of lipid mediator–directed therapies
for asthma and other lung pathologies (14). The study by Zhao
and colleagues (8) points us toward novel approaches to understand
this important and almost omnipresent airway response, and may
lead to the development of new therapies for chronic lung conditions
characterized by harmful mucus hypersecretion. n
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